Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hereditary Corneal Dystrophy Clear all
Recruiting Phase 2 Interventional

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

NCT05003986
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Interventions
Sparsentan
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Los Angeles, California • Wilmington, Delaware • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 28, 2026, 4:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

PIONEER: Intraoperative and Perioperative OCT Study

NCT02423161
View directory record Official record
Conditions
Retinal Detachment, Epiretinal Membrane, Macular Hole, Fuchs Endothelial Dystrophy
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 28, 2026, 4:45 PM EDT
Not yet recruiting Phase 2 Interventional

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07729137
View directory record Official record
Conditions
Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation, Corneal Endothelial Cell Loss, Corneal Endothelial Disorder, Corneal Endothelial Dystrophy 1, Endothelial Cell Loss, Corneal, Pseudophakic Bullous Keratopathy, Pseudophakic Bullous Keratopathy (PBK)
Interventions
150K cells, 500K cells, Placebo
Biological · Procedure
Lead sponsor
Emmecell
Industry
Eligibility
21 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 28, 2026, 4:45 PM EDT
Completed No phase listed Observational

Air Optix® Night and Day® Aqua Therapeutic Wear

NCT05956535
View directory record Official record
Conditions
Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy
Interventions
Lotrafilcon A contact lenses, Balafilcon A contact lenses
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Delray Beach, Florida • St Louis, Missouri • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Not applicable Interventional Results available

Impact of Donor Diabetes on DMEK Success and Endothelial Cell Loss

NCT05134480
View directory record Official record
Conditions
Corneal Endothelial Decompensation, Fuchs' Endothelial Dystrophy
Interventions
Descemet membrane endothelial keratoplasty
Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
30 Years to 90 Years
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Indianapolis, Indiana • Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 28, 2026, 4:45 PM EDT
Recruiting Phase 2 Interventional

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

NCT04440280
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
N-acetyl cysteine (NAC) 10% solution, N-acetyl cysteine (NAC) 20% solution, Visine Dry Eye Relief eye drops
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty

NCT01853696
View directory record Official record
Conditions
Fuchs' Dystrophy, Corneal Edema
Interventions
loteprednol etabonate, prednisolone acetate 1%
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 28, 2026, 4:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Early Experience With Descemet's Stripping Automated Endothelial Keratoplasty

NCT00744796
View directory record Official record
Conditions
Corneal Edema Secondary to Corneal Endothelial Dystrophy
Interventions
DSAEK, Anterior Segment Optical Coherence Topography (OCT), Best Spectacle Corrected Visual Acuity (BSCVA)
Procedure · Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05376176
View directory record Official record
Conditions
Fuchs Endothelial Corneal Dystrophy
Interventions
STN1010904 ophthalmic suspension 0.03% BID, STN1010904 ophthalmic suspension 0.1% BID, Placebo (Vehicle) BID
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Indianapolis, Indiana • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Early Phase 1 Interventional

Netarsudil Use After Descemetorhexis Without Endothelial Keratoplasty

NCT04057053
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Cataract
Interventions
Netarsudil 0.02% Ophthalmic Solution
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
50 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Two Steroid Regimens to Prevent Transplant Rejection After Corneal Transplant (DMEK)

NCT01448213
View directory record Official record
Conditions
Fuchs' Dystrophy, Bullous Keratopathy
Interventions
Prednisolone acetate, Fluorometholone
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2014 · Synced Sep 28, 2026, 4:45 PM EDT
Completed No phase listed Observational

Studies in Families With Corneal Dystrophy or Other Inherited Corneal Diseases

NCT00357435
View directory record Official record
Conditions
Corneal Dystrophies, Hereditary, Corneal Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
4 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Bethesda, Maryland • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

NCT03248037
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Bullous Keratopathy
Interventions
Netarsudil, Placebo
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Not applicable Interventional Results available

Optimizing the Ocular Surface Prior to Cataract Surgery

NCT02766907
View directory record Official record
Conditions
Corneal Dystrophy, Epithelial Basement Membrane
Interventions
cryopreserved amniotic membrane
Device
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 28, 2026, 4:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

OCT in Diagnosis of Irregular Corneas

NCT03504800
View directory record Official record
Conditions
Keratoconus, Corneal Opacity, Corneal Dystrophy
Interventions
Optical Coherence Tomography
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
14 Years to 85 Years
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2031
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 28, 2026, 4:45 PM EDT
Recruiting No phase listed Observational

OCT in Fuchs' Dystrophy

NCT04258787
View directory record Official record
Conditions
Fuchs Dystrophy, Pseudophakic Bullous Keratopathy
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 28, 2026, 4:45 PM EDT
Terminated No phase listed Observational

Using the Optovue OCT to Select IOL Power

NCT01361282
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Cataract
Interventions
Not listed
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 28, 2026, 4:45 PM EDT
Terminated No phase listed Observational

The Natural History of Mucolipidosis Type IV

NCT01067742
View directory record Official record
Conditions
Mucolipidosis Type IV
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
1 Year to 64 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Trial of TTHX1114 in People With CED

NCT04812067
View directory record Official record
Conditions
Corneal Endothelial Dystrophy
Interventions
TTHX1114
Drug
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia • Washington, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

NCT04051463
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Netarsudil Ophthalmic Solution, Placebo
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 28, 2026, 4:45 PM EDT
Not listed Phase 4 Interventional

Evaluating Results of Neusidl Corneal Inserter in Descemet's Stripping Automated Endothelial Keratoplasty (DSAEK)

NCT01357122
View directory record Official record
Conditions
Fuchs' Corneal Endothelial Dystrophy
Interventions
NCI Insertion, Standard Forceps Insertion
Device · Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Sep 28, 2026, 4:45 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessment of Corneal Endothelial Function Following Hypoxic Stress

NCT04175938
View directory record Official record
Conditions
Fuchs' Endothelial Corneal Dystrophy
Interventions
Wearing of contact lens
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 28, 2026, 4:45 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.

NCT04018417
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy
Interventions
Amphotericin B
Drug
Lead sponsor
Cornea Research Foundation of America
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 28, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

TTHX1114(NM141) in Combination With DWEK/DSO

NCT04676737
View directory record Official record
Conditions
Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Fuchs
Interventions
TTHX1114(NM141)
Drug
Lead sponsor
Trefoil Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Long Beach, California • Petaluma, California • Deerfield Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 28, 2026, 4:45 PM EDT